Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind controlled study of intravesical 3% hypertonic saline versus normal saline after TURBT for non-muscle-invasive bladder cancer
MOH_2020-10-11_009390Phase 2Not yet recruiting
- Sponsor
- פרופ' דן ליבוביץ
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of hypertonic saline in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by פרופ' דן ליבוביץ. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
hypertonic saline
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on MOH_2020-10-11_009390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-11_009390.